Research on Bone Metabolism
Hypercalcaemia crisis: A retrospective series of 143 cases
Liu Yang, Wang Xianling, Guo Qinghua, Du Jin, Pei Yu, Ba Jianming, Gu Weijun, Dou Jingtao, Lyu Zhaohui, Mu Yiming
Published 2024-02-25
Cite as Chin J Endocrinol Metab, 2024, 40(2): 115-120. DOI: 10.3760/cma.j.cn311282-20230616-00276
Abstract
ObjectiveThe study retrospectively analyzed the etiology, clinical manifestations, emergency treatment and etiological treatment of a large sample of cases with hypercalcemic crisis.
MethodsThe clincial data of patients with hypercalcaemia cirisis who were administered in First Medical Center of Chinese PLA General Hospital from January 2009 to July 2022 were analyzed, inculding the general data, clinical manifestations, etiology, photographic examination, emergency treatment, etiological treatment, serological examination before and after treatment, pathological immunohistochemical findings and prognosis.
ResultsA total of 143 hypercalcaemia crisis patients(84 males and 59 females) with a mean age of 53.51±16.60 were enrolled. The most common disease was hyperparathyroidism(62/143), followed by solid malignancy(57/143) and multiple myeloma(12/143). Patients presented with digestive system symptoms at 76.91%, followed by neurological symptoms at 63.60%, urinary system symptoms at 58.76%, musculoskeletal symptoms at 55.23%, and cardiovascular system symptoms at 32.91%. After emergency calcium-lowering treatment, the remission rate of hypercalcemic crisis in 143 patients was 100%(143/143), and after etiological treatment, the remission rate of hypercalcemia was 85.31%(122/143).
ConclusionEarly identification, emergency treatment and etiology treatment of hypercalcaemia crisis are essential. Effective treament with comprehensive calcium reduction can quickly relieve clinical symptoms and create opportunities for treatment for the cause. Targeted etiological interventions can lead to the correction or long-term remission of hypercalcemia.
Key words:
Hypercalcaemia crisis; Emergency treatment; Cause of disease; Clinical manifestation
Contributor Information
Liu Yang
Department of Endocrinology, the First Medical Center, Chinese PLA General Hospital, Beijing 100853, China
Liu Yang is working at the Department of Endocrinology, Shexian Hospital, Handan 056400, China
Wang Xianling
Department of Endocrinology, the First Medical Center, Chinese PLA General Hospital, Beijing 100853, China
Guo Qinghua
Department of Endocrinology, the First Medical Center, Chinese PLA General Hospital, Beijing 100853, China
Du Jin
Department of Endocrinology, the First Medical Center, Chinese PLA General Hospital, Beijing 100853, China
Pei Yu
Department of Endocrinology, the First Medical Center, Chinese PLA General Hospital, Beijing 100853, China
Ba Jianming
Department of Endocrinology, the First Medical Center, Chinese PLA General Hospital, Beijing 100853, China
Gu Weijun
Department of Endocrinology, the First Medical Center, Chinese PLA General Hospital, Beijing 100853, China
Dou Jingtao
Department of Endocrinology, the First Medical Center, Chinese PLA General Hospital, Beijing 100853, China
Lyu Zhaohui
Department of Endocrinology, the First Medical Center, Chinese PLA General Hospital, Beijing 100853, China
Mu Yiming
Department of Endocrinology, the First Medical Center, Chinese PLA General Hospital, Beijing 100853, China